- Home
- BOLD vs BCTX Comparison
BOLD vs BCTX Comparison
Compare BOLD & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | BCTX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 28.8M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOLD | BCTX |
|---|---|---|
| Price | $1.22 | $4.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $40.00 |
| AVG Volume (30 Days) | 125.9K | ★ 875.9K |
| Earning Date | 11-05-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $4.10 |
| 52 Week High | $2.54 | $98.20 |
Technical Indicators
Market Signals| Indicator | BOLD | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 41.08 |
| Support Level | $1.19 | $4.10 |
| Resistance Level | $1.31 | $4.56 |
| Average True Range (ATR) | 0.07 | 0.62 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 12.50 | 10.69 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.